Trial Profile
Pilot 2: Glucagon-like Peptide-1 in Sleep Disordered Breathing
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary)
- Indications Sleep apnoea syndrome
- Focus Therapeutic Use
- 13 Apr 2016 Status changed from active, no longer recruiting to completed.
- 03 Aug 2015 Planned number of patients changed from 20 to 30 as per ClinicalTrials.gov record.
- 03 Aug 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Dec 2015 as per ClinicalTrials.gov record.